Date:2/27/2009

llars, except per share amounts) ------------------------------------------------------------------------- Period from December 1, 1987 to Years ended November 30, November 30, 2008 2007 2006 2008 ------------------------------------------------------------------------- Expenses: Research and development $ 8,794 $ 12,039 $ 32,732 $ 247,711 General and administration 8,098 14,259 19,251 125,326 Foreign exchange loss (gain) (305) 1,977 104 10,665 ------------------------------------------------------------------------- Loss before the undernoted (16,587) (28,275) (52,087) (383,702) Interest expense on senior convertible notes payable - (5) (930) (1,279) Accretion in carrying value of senior convertible notes payable - (728) (7,824) (10,294) Amortization of deferred financing costs - (154) (2,495) (3,057) Loss on extinguishment of senior convertible notes payable - (1,754) (4,995) (6,749) Investment income 513 1,310 1,971 13,838 Change in fair value of embedded derivatives - 829 - 829 ------------------------------------------------------------------------- Loss and comprehensive loss for the period (16,074) (28,777) (66,360) (
'/>"/>

SOURCE Vasogen Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Vasogen Announces Sale of Patent Application and Provides Corporate Update
2. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
3. Vasogen Provides Corporate Update
4. Vasogen Announces Third Quarter 2008 Results
5. Vasogen Announces Second Quarter 2008 Results
6. Vasogen Provides Corporate Update
7. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
9. Vasogen Announces Implementation of Strategic Restructuring Plan
10. Vasogen Announces First Quarter 2008 Results
11. Vasogen to Webcast its Annual Meeting